It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Why pharmaceuticals are a key issue in the ongoing U.S.-China conflict

Commentary / Japan | Geoeconomic Briefing Feb 21, 2023

Why pharmaceuticals are a key issue in the ongoing U.S.-China conflict

by Yoshiyuki Sagara

Beijing has control over the chokepoints — active pharmaceutical ingredients and raw materials — of pharmaceutical supply chains.

Priority review status given to Alzheimer's drug developed by Eisai and Biogen

National Jan 30, 2023

Priority review status given to Alzheimer's drug developed by Eisai and Biogen

The companies said priority review in Japan is granted to new medicines recognized as having high medical utility for serious diseases.

In China, no easy way to get Pfizer's COVID drug Paxlovid

Asia Pacific Jan 16, 2023

In China, no easy way to get Pfizer's COVID drug Paxlovid

Beijing has acknowledged that supplies are still insufficient to meet demand, even as millions of courses of the treatment were shipped to the country recently.

Pfizer's bivalent vaccine linked to rare strokes in older people in preliminary U.S. data

World / Science & Health Jan 14, 2023

Pfizer's bivalent vaccine linked to rare strokes in older people in preliminary U.S. data

The early finding still needs more investigation, and recommendations for the vaccine have not been changed, a statement by the U.S. Food and Drug Administration said.

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine

Business Jan 13, 2023

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine

An approval would give Japan a homegrown mRNA vaccine — a vaccine type that has played a dominant role in the country's COVID-19 inoculation drive to this point.

Health ministry suggests restricting bulk drug purchases amid hoarding fears

National Jan 11, 2023

Health ministry suggests restricting bulk drug purchases amid hoarding fears

by Kanako Takahara

The message follows reports of Chinese people in the country buying medicine in bulk and mailing it to friends and families back home.

Eisai shares jump after FDA approves Alzheimer’s drug lecanemab

Business / Financial Markets Jan 10, 2023

Eisai shares jump after FDA approves Alzheimer’s drug lecanemab

by Kanoko Matsuyama

The drug, to be sold under the brand name Leqembi, was approved by the Food and Drug Administration under an accelerated pathway.

China in talks with Pfizer for generic COVID drug

Asia Pacific / Science & Health Jan 7, 2023

China in talks with Pfizer for generic COVID drug

Beijing is in talks with the drugmaker to secure a license that will allow domestic firms to manufacture and distribute a generic version of its Paxlovid antiviral drug.

Shionogi's COVID-19 pill may get China approval in March

Business / Corporate Jan 6, 2023

Shionogi's COVID-19 pill may get China approval in March

by Kanoko Matsuyama and Grace Huang

The Japanese drugmaker has been submitting data to regulators in China and expects Xocova to be authorized for use as early as this quarter, Chief Executive Officer Isao Teshirogi said.

Cancer vaccine hunt finally makes progress

Commentary / World Jan 4, 2023

Cancer vaccine hunt finally makes progress

by Lisa Jarvis

A small study shows promise in deploying mRNA technology against melanoma — but fighting tumors is vastly more complex than tackling COVID-19.

China's COVID wave sparks scramble for vital drugs across Asia

Asia Pacific Dec 30, 2022

China's COVID wave sparks scramble for vital drugs across Asia

by Jennifer Creery

Beijing’s decision to abruptly remove most pandemic restrictions with little preparation is driving an unprecedented number of cases, leaving hospitals and funeral homes overwhelmed.

Tokyo firm targets blood tests for Alzheimer's in wake of therapy breakthrough

Business / Corporate Dec 28, 2022

Tokyo firm targets blood tests for Alzheimer's in wake of therapy breakthrough

by Kanoko Matsuyama

Fujirebio Holding is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests.

« 1 … 4 5 6 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times